The historical rank and industry rank for SAB Biotherapeutics's Equity-to-Asset or its related term are showing as below:
SABS'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.13 Med: 0.62 Max: 0.91
Current: 0.69
During the past 5 years, the highest Equity to Asset Ratio of SAB Biotherapeutics was 0.91. The lowest was -0.13. And the median was 0.62.
SABS's Equity-to-Asset is ranked better than 52.84% of 1512
companies
in the Biotechnology industry
Industry Median: 0.67
vs SABS: 0.69
SAB Biotherapeutics Equity-to-Asset Historical Data
The historical data trend for SAB Biotherapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SAB Biotherapeutics's Equity-to-Asset
For the Biotechnology subindustry, SAB Biotherapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SAB Biotherapeutics's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where SAB Biotherapeutics's Equity-to-Asset falls into.
SAB Biotherapeutics Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
SAB Biotherapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SAB Biotherapeutics (NAS:SABS) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
SAB Biotherapeutics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of SAB Biotherapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SABS has been successfully added to your 